Literature DB >> 22359067

Clinical overview of cutaneous features in hypereosinophilic syndrome.

Sabine Gisela Plötz1, Bettina Hüttig, Birgit Aigner, Christian Merkel, Knut Brockow, Cezmi Akdis, Ulf Darsow, Johannes Ring.   

Abstract

The hypereosinophilic syndromes (HES) are a heterogeneous group of disorders defined as persistent and marked blood eosinophilia of unknown origin with systemic organ involvement. HES is a potentially severe multisystem disease associated with considerable morbidity. Skin involvement and cutaneous findings frequently can be seen in those patients. Skin symptoms consist of angioedema; unusual urticarial lesions; and eczematous, therapy-resistant, pruriginous papules and nodules. They may be the only obvious clinical symptoms. Cutaneous features can give an important hint to the diagnosis of this rare and often severe illness. Based on advances in molecular and genetic diagnostic techniques and on increasing experience with characteristic clinical features and prognostic markers, therapy has changed radically. Current therapies include corticosteroids, hydroxyurea, interferon-α, the tyrosine kinase inhibitor imatinib mesylate, and (in progress) the monoclonal anti-interleukin-5 antibodies. This article provides an overview of current concepts of disease classification, different skin findings, and therapy for HES.

Entities:  

Mesh:

Year:  2012        PMID: 22359067     DOI: 10.1007/s11882-012-0241-z

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  109 in total

1.  Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

Authors:  Amy D Klion; Bruce S Bochner; Gerald J Gleich; Thomas B Nutman; Marc E Rothenberg; Hans-Uwe Simon; Michael E Wechsler; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2006-05-03       Impact factor: 10.793

2.  [Hypereosinophilic syndrome with pachyderma preceding lymphoma. Treatment with interferon alpha].

Authors:  I Moraillon; M Bagot; I Bournerias; L Prin; J Wechsler; J Revuz
Journal:  Ann Dermatol Venereol       Date:  1991       Impact factor: 0.777

3.  Eosinophilic myositis with eosinophilic cellulitislike skin lesions. Association with increased serum levels of eosinophil cationic protein and interleukin-5.

Authors:  R M Trüeb; J Lübbe; R Torricelli; R G Panizzon; B Wüthrich; G Burg
Journal:  Arch Dermatol       Date:  1997-02

Review 4.  Dermatologic manifestations of the hypereosinophilic syndromes.

Authors:  Kristin M Leiferman; Gerald J Gleich; Margot S Peters
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

5.  A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.

Authors:  R T Schooley; M A Flaum; H R Gralnick; A S Fauci
Journal:  Blood       Date:  1981-11       Impact factor: 22.113

Review 6.  The hypereosinophilic syndrome: clinical features, laboratory findings and treatment.

Authors:  C J Spry
Journal:  Allergy       Date:  1982-11       Impact factor: 13.146

7.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Authors:  Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; Giovanni Martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

8.  Kimura's disease with generalized lymphadenopathy demonstrated by positron emission tomography scan.

Authors:  Tso-Fu Wang; Shu-Hsin Liu; Chih-Hao K Kao; Sung-Chao Chu; Ruey-Ho Kao; Chi-Cheng Li
Journal:  Intern Med       Date:  2006-07-18       Impact factor: 1.271

9.  A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5.

Authors:  D Brugnoni; P Airó; G Rossi; A Bettinardi; H U Simon; L Garza; C Tosoni; R Cattaneo; K Blaser; A Tucci
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

10.  Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.

Authors:  Srdan Verstovsek; Ayalew Tefferi; Hagop Kantarjian; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Pat Ault; Carlos Bueso-Ramos; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

View more
  4 in total

1.  A Case of Focal Eosinophilic Myositis Associated with Hypereosinophilic Syndrome: A Rare Case Report.

Authors:  Joon Min Jung; Mi Hye Lee; Chong Hyun Won; Sung Eun Chang; Mi Woo Lee; Jee Ho Choi; Kee Chan Moon
Journal:  Ann Dermatol       Date:  2015-10-02       Impact factor: 1.444

2.  Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome.

Authors:  Maira Renata Merlotto; Lucas Oliveira Cantadori; Delmo Sakabe; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

3.  Idiopathic Hypereosinophilic Syndrome With Cutaneous Manifestations and Flame Figures: A Spectrum of Eosinophilic Dermatoses Whose Features Overlap With Wells' Syndrome.

Authors:  Sabrina M Smith; Elizabeth A Kiracofe; Lindsey N Clark; Alejandro A Gru
Journal:  Am J Dermatopathol       Date:  2015-12       Impact factor: 1.533

4.  Angioedema without wheals: a clinical update.

Authors:  Okan Gülbahar
Journal:  Balkan Med J       Date:  2021-03       Impact factor: 2.021

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.